This is a double-blind, placebo-controlled, parallel group study designed to assess the
efficacy of full spectrum CBD and broad spectrum CBD, compared to a placebo control (PC), to
reduce drinking in participants with alcohol use disorder. If eligible for the study,
subjects will be randomized to receive one of the conditions for 12 weeks.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of Colorado, Denver
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)